Dermapharm Hldg Se (DMPHF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to the Dermapharm Hldg Se Q2 2026 Results Conference Call. I'm Moritz, your Chorus Call Operator. I would like to remind you that all participants will be in a listen-only mode and the conference is being recorded. The presentation will be followed by a question and answer session. You can register for questions at any time by pressing star and 1 on your telephone. For operator assistance, please press star and 0. The conference must not be recorded for publication or broadcast. It's my pleasure to hand over to Britta Hamberger. Please go ahead. Thank you for your kind introduction. Ladies and gentlemen, welcome to Dermapharm's H1 webcast and thank you for joining us today. With me is our Chief Financial Officer Christof Dreibholz and our Chief Marketing Officer Andreas Eberhorn. Andreas and Christof will guide you through today's presentation and afterwards we will be open with Q&A. Andreas, the floor is yours. Thanks a lot, Britta. Also welcome from my side. For the first half of 2026, I want to show you a few highlights we see which support the very several trends we see on the operational side, structured in a way, as you know, in branded other healthcare and parallel import segments. If we look briefly at the branded piece, we see nice growth in our core business, Germany. Specifically, the brands that we focus on, where we put our investment in, really grow nicely and show both internally but also on the market growth above the relevant market. Is it brands like Miditin, Tromkatin or Ketocilin and develop further nicely. As you know, after the acquisition of Muco's business from Nestle, we had the task also to relaunch Woop Enzyme after a period of supply issues in the market, which is really nicely done in Germany. And end of H1, ...